Chordia Therapeutics, a research-based drug discovery company specializing in oncology, has raised approximately 3 billion yen in a Series B round of financing from a venture capital investment alliance.

Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-iCAP No.1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head Office: Sakyo-ku, Kyoto; Representative Director: Koji Murota) as the general partner, is pleased to announce that Chordia Therapeutics Inc. ("Chordia") (CEO: Hiroshi Miyake, Location: Fujisawa City, Kanagawa Prefecture), a company that has discovered several First-in-Class anti-cancer drug candidates and is expected to make great strides toward becoming a world-class drug discovery venture. This investment is in response to Chordia's Series B round, in which Chordia raised a total of approximately 3 billion yen through a third-party allocation of new shares.

Kyoto iCAP hopes that this capital increase will accelerate the research and development of Chordia and that the company's anticancer drug candidate will serve as a gospel for cancer patients and their families. The Series B round was led by Jafco Inc. and Kyoto iCAP, with participation from Shinsei Capital Partners, Mitsubishi UFJ Capital, SMBC Venture Capital, and Nippon Venture Capital.

Chordia Therapeutics Corporation Overview

Establishment	October 12, 2017
Business	Research and development of novel anticancer agents
Head Office Location	Fujisawa City, Kanagawa Prefecture
President & CEO	Hiroshi Miyake